These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 35744792)

  • 1. Dystrophin Protein Quantification as a Duchenne Muscular Dystrophy Diagnostic Biomarker in Dried Blood Spots Using Multiple Reaction Monitoring Tandem Mass Spectrometry: A Preliminary Study.
    Nimer RM; Sumaily KM; Almuslat A; Abdel Jabar M; Sabi EM; Al-Muhaizea MA; Abdel Rahman AM
    Molecules; 2022 Jun; 27(12):. PubMed ID: 35744792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CFTR protein quantification as a cystic fibrosis diagnostic biomarker in dried blood spots using multiple reaction monitoring tandem mass spectrometry.
    Sumaily KM; Nimer R; Alzahrani M; Abdel Jabar M; Alodib A; Sabi EM; Nizami I; Abdel Rahman AM
    J Pharm Biomed Anal; 2022 Jul; 216():114801. PubMed ID: 35504217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dystrophin and mini-dystrophin quantification by mass spectrometry in skeletal muscle for gene therapy development in Duchenne muscular dystrophy.
    Farrokhi V; Walsh J; Palandra J; Brodfuehrer J; Caiazzo T; Owens J; Binks M; Neelakantan S; Yong F; Dua P; Le Guiner C; Neubert H
    Gene Ther; 2022 Nov; 29(10-11):608-615. PubMed ID: 34737451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Proof of Principle Proteomic Study Detects Dystrophin in Human Plasma: Implications in DMD Diagnosis and Clinical Monitoring.
    Rossi R; Johansson C; Heywood W; Vinette H; Jensen G; Tegel H; Jiménez-Requena A; Torelli S; Al-Khalili Szigyarto C; Ferlini A
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Establishment of a Triple Quadrupole HPLC-MS Quantitation Method for Dystrophin Protein in Mouse and Human Skeletal Muscle.
    Tominari T; Takatoya M; Matsubara T; Matsunobe M; Arai D; Matsumoto C; Hirata M; Yoshinouchi S; Miyaura C; Itoh Y; Komaki H; Takeda S; Aoki Y; Inada M
    Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of capillary Western immunoassay (Wes) for quantification of dystrophin levels in skeletal muscle of healthy controls and individuals with Becker and Duchenne muscular dystrophy.
    Beekman C; Janson AA; Baghat A; van Deutekom JC; Datson NA
    PLoS One; 2018; 13(4):e0195850. PubMed ID: 29641567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antisense Oligonucleotide Treatment in a Humanized Mouse Model of Duchenne Muscular Dystrophy and Highly Sensitive Detection of Dystrophin Using Western Blotting.
    Maruyama R; Yokota T
    Methods Mol Biol; 2021; 2224():203-214. PubMed ID: 33606217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The discovery of the DNA methylation episignature for Duchenne muscular dystrophy.
    Schreyer L; Reilly J; McConkey H; Kerkhof J; Levy MA; Hu J; Hnaini M; Sadikovic B; Campbell C
    Neuromuscul Disord; 2023 Jan; 33(1):5-14. PubMed ID: 36572586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Therapy of Duchenne muscular dystrophy with umbilical cord blood stem cell transplantation].
    Zhang C; Feng HY; Huang SL; Fang JP; Xiao LL; Yao XL; Chen C; Ye X; Zeng Y; Lu XL; Wen JM; Zhang WX; Li Z; Feng SW; Xu HG; Huang K; Zhou DH; Chen W; Xie YM; Xi J; Zhang M; Li Y; Liu Y
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2005 Aug; 22(4):399-405. PubMed ID: 16086277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Duchenne and Becker muscular dystrophy: a molecular and immunohistochemical approach.
    Freund AA; Scola RH; Arndt RC; Lorenzoni PJ; Kay CK; Werneck LC
    Arq Neuropsiquiatr; 2007 Mar; 65(1):73-6. PubMed ID: 17420831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Duchenne and Becker Muscular Dystrophies: A Review of Animal Models, Clinical End Points, and Biomarker Quantification.
    Wilson K; Faelan C; Patterson-Kane JC; Rudmann DG; Moore SA; Frank D; Charleston J; Tinsley J; Young GD; Milici AJ
    Toxicol Pathol; 2017 Oct; 45(7):961-976. PubMed ID: 28974147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biochemical characterization of patients with in-frame or out-of-frame DMD deletions pertinent to exon 44 or 45 skipping.
    Anthony K; Arechavala-Gomeza V; Ricotti V; Torelli S; Feng L; Janghra N; Tasca G; Guglieri M; Barresi R; Armaroli A; Ferlini A; Bushby K; Straub V; Ricci E; Sewry C; Morgan J; Muntoni F
    JAMA Neurol; 2014 Jan; 71(1):32-40. PubMed ID: 24217213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intragenic deletions in the dystrophin gene in 211 Pakistani Duchenne muscular dystrophy patients.
    Hassan MJ; Mahmood S; Ali G; Bibi N; Waheed I; Rafiq MA; Ansar M; Ahmad W
    Pediatr Int; 2008 Apr; 50(2):162-6. PubMed ID: 18353051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. De novo revertant fiber formation and therapy testing in a 3D culture model of Duchenne muscular dystrophy skeletal muscle.
    Ebrahimi M; Lad H; Fusto A; Tiper Y; Datye A; Nguyen CT; Jacques E; Moyle LA; Nguyen T; Musgrave B; Chávez-Madero C; Bigot A; Chen C; Turner S; Stewart BA; Pegoraro E; Vitiello L; Gilbert PM
    Acta Biomater; 2021 Sep; 132():227-244. PubMed ID: 34048976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Causes of clinical variability in Duchenne and Becker muscular dystrophies and implications for exon skipping therapies.
    Hoffman EP
    Acta Myol; 2020 Dec; 39(4):179-186. PubMed ID: 33458572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deletion mutations in the dystrophin gene of Saudi patients with Duchenne and Becker muscular dystrophy.
    Al-Jumah M; Majumdar R; Al-Rajeh S; Chaves-Carballo E; Salih MM; Awada A; Al-Shahwan S; Al-Uthaim S
    Saudi Med J; 2002 Dec; 23(12):1478-82. PubMed ID: 12518196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Detection of new mutations in the dystrophin gene by denaturing high-performance liquid chromatography].
    Chen YN; Zhou X; Jin CL; Xu Y; Lin CK; Cao LH; Li N; Zhang X; Luo Y
    Zhonghua Er Ke Za Zhi; 2007 Jun; 45(6):413-6. PubMed ID: 17880784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exon skipping quantification by quantitative reverse-transcription polymerase chain reaction in Duchenne muscular dystrophy patients treated with the antisense oligomer eteplirsen.
    Anthony K; Feng L; Arechavala-Gomeza V; Guglieri M; Straub V; Bushby K; Cirak S; Morgan J; Muntoni F
    Hum Gene Ther Methods; 2012 Oct; 23(5):336-45. PubMed ID: 23075107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A highly sensitive and quantitative assay for dystrophin protein using Single Molecule Count Technology.
    Ishii MN; Quinton M; Kamiguchi H
    Neuromuscul Disord; 2023 Oct; 33(10):737-743. PubMed ID: 37666691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exon-skipped dystrophins for treatment of Duchenne muscular dystrophy: mass spectrometry mapping of most exons and cooperative domain designs based on single molecule mechanics.
    Krieger CC; Bhasin N; Tewari M; Brown AE; Safer D; Sweeney HL; Discher DE
    Cytoskeleton (Hoboken); 2010 Dec; 67(12):796-807. PubMed ID: 20886611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.